BAX Baxter International Inc.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Baxter International (NYSE: BAX)
›
Baxter International (NYSE: BAX) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 37,500 employees.
The shares were at 25.39 USD on 19 November 2026, up 35.9% over 52 weeks. Its 52-week range is 15.73 USD to 30.00 USD: the price is 15.4% below the high and 61.4% above the low.
Its market capitalisation is 13.14B USD. It pays a dividend yielding 0.15% (it pays out 155% of its earnings), against a median of 1.00% among the dividend payers in that peer group.
Baxter International reports return on equity of -15.6%, an operating margin of 7.6% and revenue up 5.0% year over year.
Its debt exceeds its cash by 6.83B USD, a debt-to-equity ratio of 1.60. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Hold; their mean price target of 27.25 USD is 7.3% above the current price. The next earnings report is expected on 11 February 2027.